MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Sharma et al. investigated the state and adoption of Hospital Based Health Technology Assessment (HB-HTA) in hospital management. By administering questionnaires to healthcare professionals, the authors aimed to assess HTA knowledge and analyze perspectives. The results revealed a notable interest in HB-HTA as a strategic tool for supporting clinical and organizational decision-making processes, particularly in the evolving healthcare landscape of Italy with increased funds from the National Recovery and Resilience Plan (NRRP).

On January 23, 2024, the Ministry of Health introduced a new national catalog, which guarantees the Spanish population's genetic tests nationwide. Currently, the catalog includes 672 tests in eight disease areas, including adult and pediatric oncohematology, pharmacogenomics, hereditary metabolic and mitochondrial diseases, and others. Twelve more disease areas are expected to be added in 2024.

The LEA catalog was brought in 2017, but the tariffs were approved in 2023. The new tariffs for outpatient specialist care were supposed to enter into force on January 1, 2024, but the adoption of new tariffs was postponed to April 1, 2024, due to the technical inability of the Regions to implement the change in time.

In Belgium, kidney dialysis is reimbursed under a specific agreement (Convention) between the National Institute for Health and Disability Insurance (INAMI-RIZIV) and chronic kidney failure centers starting in 2018. The current update of the Convention came into force on January 1, 2024, and is valid until December 31, 2026. Four new Pseudo-nomenclature codes for informing and training patients were added.

In January 2024, eight NHS Genomic Networks of Excellence were launched within the NHS Genomic Medicine Service (GMS). NHS England is funding these innovative networks to develop the evidence and model of adoption for cutting-edge genomic advances and technology applications and inform commissioning decisions.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Siontis et al. conducted a systematic review of the clinical evidence supporting 71 high-risk cardiovascular devices before and after market access in the European Union (CE-marking) between 2000 and 2021. The authors aimed to assess the quantity and quality of published studies, revealing a notable insufficiency in publicly available data and a lack of randomized clinical trial data published before CE-mark approval, with most studies being non-randomized and conducted in small populations without the provision of power calculations.

In January 2024, the Dutch Healthcare Institute (ZIN) published an update of the “Guideline for conducting health economic evaluations”.

MTRC is re-starting the release of educational videos on its YouTube channel. Videos will cover a wide range of topics, including reimbursement, funding, health technology assessment, and clinical and economic evidence requirements for medical technologies in European countries.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Garcia Gonzalez-Moral et al. conducted a mapping review to identify various methodologies employed in horizon scanning (HS) and foresight practices for medical technology (MedTech) innovation, with a specific focus on informing healthcare decision-making. The authors uncovered 25 distinct methods of HS, emphasizing the prevalence of combined approaches. Their findings underscored the necessity for greater transparency and consistency in methodologies to enhance the quality and timeliness of decision-making processes in the field of MedTech.

New Greek DRG system (Gr-DRG), which has been developed in collaboration with German Institute for the Hospital Remuneration System (InEK), will be implemented in all Greek hospitals since March 01, 2024.

In January 2024, NHS England issued an updated version of the National Genomic Test Directory for 2024/2025, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Six new codes (test-indication combinations) were introduced in the Test Directory for cancer, and four new codes in the Test Directory for rare and inherited diseases.

On January 15, 2024, the National Institute for Health and Disability Insurance (INAMI-RIZIV) released an updated DRG system for 2024. No significant changes were made aand no new APR-DRGs were added; thus. The reimbursement tariffs were increased by about 5%.